Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was extended, in our case — was somehow relaxing and invigorating, since the usual weekday routine has predictably returned. After all, the world keeps spinning. With this in mind, why not have a cup of stimulation and give it a push? Our choice today is vanilla caramel cream. Please feel free to join us. Meanwhile, here are a few items of interest to help you get going. We hope your day is productive and peaceful. …
Health care providers will begin receiving the first 3.9 million doses of the newly authorized Johnson & Johnson (JNJ) Covid-19 vaccine as early as Tuesday morning, though supply will be uneven in the coming weeks, STAT explains, citing senior Biden administration officials. The first shipments account for the entirety of J&J’s current inventory. Officials expect another 16 million doses to be available by the end of March, though J&J told the federal government that the doses will be delivered mostly toward the second half of the month.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
